Ezetimibe

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H21F2NO3
Molecular Weight	409.4252
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@@H](CC[C@@H]1[C@H](N(C1=O)C2=CC=C(F)C=C2)C3=CC=C(O)C=C3)C4=CC=C(F)C=C4

InChI

InChIKey=OLNTVTPDXPETLC-XPWALMASSA-N

InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00973
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/ezetimibe.html

Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes. Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe, administered alone is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors. Ezetimibe has a mechanism of action that differs from those of other classes of cholesterol-reducing compounds (HMG-CoA reductase inhibitors, bile acid sequestrants, fibric acid derivatives, and plant stanols). Ezetimibe does not inhibit cholesterol synthesis in the liver, or increase bile acid excretion but instead localizes and appears to act at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood; this distinct mechanism is complementary to that of HMG-CoA reductase inhibitors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Niemann-Pick C1-like protein 1 2 Target ID: CHEMBL2027 Sources: http://www.drugbank.ca/drugs/DB00973	Inhibitor 8297
Acyl coenzyme A:cholesterol acyltransferase 1 15 Target ID: CHEMBL2782 Sources: http://www.drugbank.ca/drugs/DB00973	Inhibitor 8297
Niemann-Pick C1-like protein 1 2 Target ID: CHEMBL5161 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18063367	Inhibitor 8297	200.0 nM [Ki]
Leishmania amazonensis 8 Target ID: CHEMBL612877 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27600041	Inhibitor 8297	30.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Hyperlipidemia 80 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021445Orig1s037lbl.pdf	Primary	Approved 8429	ZETIA Approved Use Ezetimibe, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Launch Date 2002
Homozygous familial hypercholesterolemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021445Orig1s037lbl.pdf	Primary	Approved 8429	ZETIA Approved Use Homozygous Familial Hypercholesterolemia (HoFH) The combination of Ezetimibe and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. Launch Date 2002
Homozygous familial sitosterolemia 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021445Orig1s037lbl.pdf	Primary	Approved 8429	ZETIA Approved Use Ezetimibe is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. Launch Date 2002

C_max

Value	Dose	Analyte	Population
64.2 ng/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15871634	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	EZETIMIBE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
70.1 ng/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15871634	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EZETIMIBE unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EZETIMIBE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
726 ng × h/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15871634	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		EZETIMIBE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
743 ng × h/mL REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15871634	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		EZETIMIBE unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		EZETIMIBE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33644733	unhealthy, 57 years n = 1 Health Status: unhealthy Age Group: 57 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33644733	Disc. AE: Liver injury... AEs leading to discontinuation/dose reduction: Liver injury Sources: https://pubmed.ncbi.nlm.nih.gov/33644733
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00867165	unhealthy, children n = 92 Health Status: unhealthy Condition: Primary hypercholesterolemia Age Group: children Population Size: 92 Sources: https://clinicaltrials.gov/ct2/show/NCT00867165	Other AEs: Epilepsy congenital, Appendicitis... Other AEs: Epilepsy congenital (serious, 1 patient) Appendicitis (serious, 1 patient) Upper respiratory tract infection (below serious, 7 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00867165
50 mg 1 times / day multiple, oral Highest studied dose Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	unhealthy n = 15 Health Status: unhealthy Population Size: 15 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01611883	unhealthy n = 75 Health Status: unhealthy Condition: Type 2 Diabetes Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT01611883	Other AEs: Cataract, Abdominal pain upper... Other AEs: Cataract (serious, 1 patient) Abdominal pain upper (serious, 1 patient) Type 2 diabetes mellitus (below serious, 7 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01611883

AEs

AE	Significance	Dose	Population
Liver injury	Disc. AE	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33644733	unhealthy, 57 years n = 1 Health Status: unhealthy Age Group: 57 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33644733
Upper respiratory tract infection	below serious, 7 patients	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00867165	unhealthy, children n = 92 Health Status: unhealthy Condition: Primary hypercholesterolemia Age Group: children Population Size: 92 Sources: https://clinicaltrials.gov/ct2/show/NCT00867165
Appendicitis	serious, 1 patient	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00867165	unhealthy, children n = 92 Health Status: unhealthy Condition: Primary hypercholesterolemia Age Group: children Population Size: 92 Sources: https://clinicaltrials.gov/ct2/show/NCT00867165
Epilepsy congenital	serious, 1 patient	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00867165	unhealthy, children n = 92 Health Status: unhealthy Condition: Primary hypercholesterolemia Age Group: children Population Size: 92 Sources: https://clinicaltrials.gov/ct2/show/NCT00867165
Type 2 diabetes mellitus	below serious, 7 patients	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01611883	unhealthy n = 75 Health Status: unhealthy Condition: Type 2 Diabetes Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT01611883
Abdominal pain upper	serious, 1 patient	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01611883	unhealthy n = 75 Health Status: unhealthy Condition: Type 2 Diabetes Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT01611883
Cataract	serious, 1 patient	10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01611883	unhealthy n = 75 Health Status: unhealthy Condition: Type 2 Diabetes Population Size: 75 Sources: https://clinicaltrials.gov/ct2/show/NCT01611883

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781		inhibitor 1852 inducer 97	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 214 P-gp 1461 CYP1A2 1524 CYP2C8/9 44 BCRP 699 OATP1B1 788	CYP 270 P-gp 1537 UGT1A1 418 UGT1A3 422 UGT2B15 203 MRP2 205	CYP1A2 701 CYP2C8/9 1

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2C8/9 44	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2C8/9 44	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0	not significant	unlikely (co-administration study) Comment: administered using cocktail approach: caffeine, tolbutamide, dextromethorphan, IV midazolam, and dapsone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=19 Page: 19.0
CYP3A 298	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes [IC50 0.25 uM]
OATP1B1 803	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/398.full.pdf#page=11 Page: 11.0	yes [IC50 2.2 uM]	unlikely Comment: page 8: R-value extrapolation indicate potential for DDI as unlikely Sources: https://dmd.aspetjournals.org/content/dmd/44/3/398.full.pdf#page=11 Page: 11.0
BCRP 773	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/398.full.pdf#page=11 Page: 11.0	yes [IC50 2.9 uM]
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes [IC50 24 uM]

Drug as victim

Target	Modality	Activity
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	no
MRP2 205	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17828742/	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes
UGT1A1 418	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes
UGT1A3 422	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes
UGT2B15 203	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_biopharmr_P1.pdf#page=18 Page: 18.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.ema.europa.eu/en/documents/assessment-report/nustendi-epar-public-assessment-report_en.pdf#page=31 Page: 31.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:49040	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49040
ChemicalBook	CB7380787	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7380787
MolPort	MolPort-005-938-627	https://www.molport.com/shop/molecule-link/MolPort-005-938-627
Selleck Chemicals	Ezetimibe(Zetia)	http://www.selleckchem.com/products/Ezetimibe(Zetia).html
ZINC	ZINC000003810860	http://zinc15.docking.org/substances/ZINC000003810860
eMolecules	2736798	https://www.emolecules.com/cgi-bin/more?vid=2736798

PubMed

Title	Date	PubMed
Molecule of the month. Ezetimibe.	2001 Apr	12819822
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.	2001 Aug	11558859
Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy.	2001 Dec	11777299
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.	2001 Jun	11375333
Ezetimibe (Schering-Plough).	2001 Mar	11575710
[Other antihyperlipidemic drugs with novel mechanism].	2001 Mar	11347153
Novel approaches to lipid lowering: what is on the horizon?	2001 Mar 8	11256846
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.	2001 Oct	11586500
[Statins remain the standard. New methods for lipid lowering therapy].	2001 Oct 18	11697281
Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.	2001 Sep	11564660
New advances in lipid-modifying therapies for reducing cardiovascular risk.	2002	11978950
Gateways to Clinical Trials.	2002 Apr	12087878
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.	2002 Dec 18	12505224
[Ezetimib. A new cholesterol absorption inhibitor].	2002 Jul	12148235
[Lipid control in the double pack. Combined drugs to achieve the goal].	2002 Jun 6	12119910
Gateways to clinical trials.	2002 May	12092009
Combination therapy for combined dyslipidemia.	2002 Nov 20	12467937
[Ezetimib--the first selective cholesterol resorption inhibitors. Strengthening of statins].	2002 Nov 28	12532546
Gateways to clinical trials.	2002 Oct	12500432
Promising therapies for cholesterol reduction.	2002 Sep	12369337
[Statins plus cholesterol resorption inhibitor. LDL goal values attainable].	2002 Sep 19	12395708
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.	2003 Apr	12713766
Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia.	2003 Apr	12713763
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.	2003 Feb 15	12586255
A novel therapeutic approach to dyslipidemia.	2003 Jan	12572626
Combination therapy for dyslipidemia.	2003 Jan	12572624
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption.	2003 Jul 1	12835406
Ezetimibe added to ongoing statin therapy reduced LDL cholesterol in primary hypercholesterolemia.	2003 Jul-Aug	12841712
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies.	2003 Jun	12846338
Sterol absorption by the small intestine.	2003 Jun	12840653
Ezetimibe for management of hypercholesterolemia.	2003 Jun	12773075
What future for combination therapies?	2003 Mar	12793597
New cholesterol-lowering drug makes its mark.	2003 Mar	12703463
New lipid-modifying therapies.	2003 Mar	12605558
Gateways to clinical trials.	2003 May	12808477
Three new drugs for hyperlipidemia.	2003 May	12802842
52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.	2003 May	12800468
[Controlling LDL cholesterol from 2 sides. "I have never seen such low LDL values"].	2003 May 15	12822234

Patents

Sample Use Guides

In Vivo Use Guide

10 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

10uM/L ezetimibe treatment of Huh7 hepatocytes significantly decreased PA-induced fat accumulation and increased PA-reduced mRNA and protein expression involved in autophagy

Name

Type

Language

Ezetimibe

Official Name

English

EZETIMIBE [USP MONOGRAPH]

Common Name

English

EZETIMIBE [JAN]

Common Name

English

EZETIMIBE [USAN]

Common Name

English

EZETIMIBE [USP-RS]

Common Name

English

EZETIMIBE [VANDF]

Common Name

English

SCH-58235

Code

English

SCH58235

Code

English

ROSZET COMPONENT EZETIMIBE

Brand Name

English

EZETIMIBE [MI]

Common Name

English

EZETIMIBE COMPONENT OF VYTORIN

Brand Name

English

NEXLIZET COMPONENT EZETIMIBE

Brand Name

English

NSC-758923

Code

English

EZETIMIBE [ORANGE BOOK]

Common Name

English

EZETIMIBE COMPONENT OF NEXLIZET

Brand Name

English

EZETIMIBE [MART.]

Common Name

English

VYTORIN COMPONENT EZETIMIBE

Brand Name

English

ZETIA

Brand Name

English

(3R,4S)-1-(P-FLUOROPHENYL)-3-((3S)-3-(P-FLUOROPHENYL)-3-HYDROXYPROPYL)-4-(P-HYDROXYPHENYL)-2-AZETIDINONE

Systematic Name

English

EZETROL

Brand Name

English

MK0653

Code

English

EZETIMIBE COMPONENT OF ROSZET

Brand Name

English

EZETIMIBE [HSDB]

Common Name

English

Ezetimibe [WHO-DD]

Common Name

English

2-AZETIDINONE, 1-(4-FLUOROPHENYL)-3-(3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL)-4-(4-HYDROXYPHENYL)-, (3R-(3.ALPHA.(S*),4.BETA.))-

Systematic Name

English

K-924 component Ezetimibe

Common Name

English

ezetimibe [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000008553